Group 1 - The core viewpoint of the news is that Kailaiying has shown significant trading activity and financial performance, with a notable increase in shareholder numbers and revenue growth [1][2]. Group 2 - On January 16, Kailaiying's stock rose by 0.78%, with a trading volume of 639 million yuan. The financing buy amount was 36.72 million yuan, while the financing repayment was 56.27 million yuan, resulting in a net financing outflow of 19.55 million yuan [1]. - As of January 16, the total balance of margin trading for Kailaiying was 853 million yuan, with a financing balance of 849 million yuan, accounting for 2.41% of the circulating market value, which is above the 50th percentile level over the past year [1]. - In terms of securities lending, on January 16, Kailaiying repaid 2,400 shares and sold 100 shares, with a selling amount of 10,700 yuan. The remaining securities lending volume was 45,900 shares, with a balance of 4.92 million yuan, also above the 50th percentile level over the past year [1]. Group 3 - As of September 30, Kailaiying had 60,100 shareholders, an increase of 45.37% compared to the previous period. The average circulating shares per person remained at 0 shares [2]. - For the period from January to September 2025, Kailaiying achieved operating revenue of 4.63 billion yuan, a year-on-year increase of 11.82%, and a net profit attributable to shareholders of 800 million yuan, up 12.66% year-on-year [2]. - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [2]. Group 4 - As of September 30, 2025, among the top ten circulating shareholders of Kailaiying, the largest shareholder was Central European Medical Health Mixed A, holding 16.3189 million shares, an increase of 34,600 shares compared to the previous period [2]. - Hong Kong Central Clearing Limited ranked as the fourth largest circulating shareholder, holding 13.2877 million shares, an increase of 626,400 shares [2]. - The sixth largest circulating shareholder, Huabao Zhongzheng Medical ETF, held 5.6467 million shares, a decrease of 1 million shares compared to the previous period [2].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Investment Rating - The report maintains a positive outlook on the CXO sector, highlighting growth potential driven by new molecular developments and recovery in domestic market conditions [2]. Core Insights - The CXO sector is experiencing a recovery in demand due to increased research activities and funding from downstream pharmaceutical companies [3][15]. - The macroeconomic environment is improving, with a favorable investment climate for the pharmaceutical and biotechnology sectors as a result of the Federal Reserve's interest rate cuts [6][29]. - Domestic healthcare investment is showing significant growth, with a total investment amount of 93.54 billion yuan in 2025, reflecting an 83.7% year-on-year increase [22][24]. - The number of new drug IND applications in China is steadily increasing, indicating a robust pipeline for future drug development [34][37]. Summary by Sections Macroeconomic Dimension - The Federal Reserve's interest rate cuts are expected to enhance the investment environment for the pharmaceutical sector, benefiting outsourcing demand from pharmaceutical companies [6][29]. - Geopolitical uncertainties are gradually being alleviated, which is expected to positively impact leading CXO companies [3][12]. Industry Dimension - The demand for CXO services is closely linked to the research activities and funding of pharmaceutical companies, with a notable increase in domestic and global investment in healthcare [15][19]. - In 2025, the total investment in China's healthcare sector reached 93.54 billion yuan, with a significant increase in the number of investment events [22][24]. - The number of new drug IND applications in China reached 1,840 in 2025, marking a 15.0% year-on-year increase [34][37]. Company Performance - The CXO sector's revenue for the first three quarters of 2025 was 69.57 billion yuan, representing a 13.0% increase year-on-year, with a net profit of 16.54 billion yuan, up 60.0% [51][57]. - Major contributors to revenue include WuXi AppTec (47%), Kanglong Chemical (15%), and Tigermed (7%) [53][57]. - The overall gross margin for the sector improved to 40.3%, reflecting operational efficiencies and scale effects [51][58].

香港联交所最新资料显示，1月9日，Schroders PLC减持凯莱英（06821）16.77万股，每股作价83.6305 港元，总金额约为1402.48万港元。减持后最新持股数目为550.56万股，最新持股比例为19.98%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新资料显示，1月9日，Schroders PLC减持凯莱英（06821）16.77万股，每股作价83.6305 港元，总金额约为1402.48万港元。减持后最新持股数目为550.56万股，最新持股比例为19.98%。 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Group 1 - Schroders PLC reduced its stake in Kintor Pharmaceutical (002821) by selling 167,700 shares at a price of HKD 83.6305 per share, totaling approximately HKD 14.0248 million [1] - After the reduction, Schroders PLC's remaining shareholding is 5.5056 million shares, representing a holding percentage of 19.98% [1]

智通财经APP获悉，香港联交所最新资料显示，1月9日，Schroders PLC减持凯莱英(06821)16.77万股， 每股作价83.6305港元，总金额约为1402.48万港元。减持后最新持股数目为550.56万股，最新持股比例 为19.98%。 ...

1月13日，凯莱英涨1.32%，截至发稿，报105.87元/股，成交9.77亿元，换手率2.88%，总市值381.76亿 元。凯莱英股价已经连续3天上涨，区间累计涨幅5.49%。 资料显示，凯莱英医药集团(天津)股份有限公司位于天津经济技术开发区第七大街71号，成立日期1998 年10月7日，上市日期2016年11月18日，公司主营业务涉及提供CMO医药外包服务。主营业务收入构成 为：小分子CDMO解决方案76.19%，新兴服务23.71%，其他0.10%。 从基金十大重仓股角度 数据显示，新沃基金旗下1只基金重仓凯莱英。新沃内需增长混合A（012143）三季度减持200股，持有 股数4800股，占基金净值比例为4.99%，位居第九大重仓股。根据测算，今日浮盈赚取约6624元。连续 3天上涨期间浮盈赚取2.64万元。 新沃内需增长混合A（012143）成立日期2021年9月9日，最新规模850.55万。今年以来收益10.7%，同 类排名761/8836；近一年收益40.04%，同类排名3488/8091；成立以来亏损43.2%。 新沃内需增长混合A（012143）基金经理为刘屾。 截至发稿，刘屾累计任职时间4 ...

香港联交所最新资料显示，1月7日，Schroders PLC减持凯莱英（002821）(06821)26.05万股，每股作价 82.7099港元，总金额约为2154.59万港元。减持后最新持股数目为574.18万股，最新持股比例为 20.84%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月7日，Schroders PLC减持凯莱英(06821)26.05万股， 每股作价82.7099港元，总金额约为2154.59万港元。减持后最新持股数目为574.18万股，最新持股比例 为20.84%。 ...